Daiichi Sankyo Co., Ltd.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 2005-09-28

Employees: 18.7K

Market Cap: -

Website: http://www.daiichisankyo.co.jp

Clinical Trials

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Phase 2

Completed

Conditions: Colorectal Neoplasm

Interventions: Drug: DS-8201a

First Posted Date: 2017-12-28

Last Posted Date: 2021-10-18

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 86

Registration Number: NCT03384940

Locations: 🇺🇸
UCLA Health, Santa Monica, California, United States
🇮🇹
Oncology Institute Veneto IOV-IRCCS, Padova, Ferrara, Italy
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 22 locations

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Phase 1

Completed

Conditions: Neoplasm Metastasis

Interventions: Drug: DS-8201a
Drug: Ritonavir
Drug: Itraconazole

First Posted Date: 2017-12-26

Last Posted Date: 2023-12-11

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT03383692

Locations: 🇯🇵
Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇯🇵
Kobe University Hospital, Kobe, Hyogo, Japan

and more 7 locations

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Phase 1

Completed

Conditions: Malignant Neoplasm of Breast

Interventions: Drug: DS-8201a

First Posted Date: 2017-12-08

Last Posted Date: 2022-04-12

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 51

Registration Number: NCT03366428

Locations: 🇯🇵
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵
Shizuoka Cancer Center, Shizuoka, Japan
🇯🇵
Toranomon Hospital, Minato-Ku, Tokyo, Japan

and more 4 locations

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Phase 2

Completed

Conditions: Neoplasm, Gastrointestinal

Interventions: Drug: Physician's Choice
Drug: DS-8201a

First Posted Date: 2017-11-06

Last Posted Date: 2022-03-18

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 233

Registration Number: NCT03329690

Locations: 🇯🇵
Hirosaki University Hospital, Hirosaki, Aomori, Japan
🇯🇵
National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan
🇯🇵
Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Fukuoka, Japan

and more 63 locations

Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy

Not Applicable

Completed

Conditions: Acute Ischemic Stroke

Interventions: Drug: DS1040b
Drug: Placebo

First Posted Date: 2017-06-26

Last Posted Date: 2021-01-28

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT03198715

Locations: 🇯🇵
Iwate Prefectural Central Hospital, Morioka, Iwate, Japan
🇯🇵
Nagasaki University Hospital, Nagasaki, Japan
🇯🇵
Japan Organization of Occupational Health and Safety Kansai Rosai Hospital, Amagasaki, Hyogo, Japan

and more 17 locations

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Phase 2

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Quizartinib

First Posted Date: 2016-12-07

Last Posted Date: 2020-02-17

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 37

Registration Number: NCT02984995

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Patritumab Deruxtecan

First Posted Date: 2016-12-02

Last Posted Date: 2024-10-30

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 182

Registration Number: NCT02980341

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Southeastern Regional Medical Center, Newnan, Georgia, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 23 locations

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

Not Applicable

Completed

Conditions: Melanoma

Interventions: Drug: PLX3397

First Posted Date: 2016-11-29

Last Posted Date: 2024-11-19

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 6

Registration Number: NCT02975700

Locations: 🇨🇳
Sun Yat-sen Hospital, Guangzhou, Guangdong, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Seodaemun-gu, Korea, Republic of

and more 2 locations

Study of CS-3150 in Patients With Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: CS-3150
Drug: Eplerenone

First Posted Date: 2016-09-07

Last Posted Date: 2018-12-21

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 1001

Registration Number: NCT02890173

Study of CS-3150 in Patients With Primary Aldosteronism

Not Applicable

Completed

Conditions: Primary Aldosteronism

Interventions: Drug: CS-3150

First Posted Date: 2016-08-31

Last Posted Date: 2018-12-21

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 44

Registration Number: NCT02885662

Locations: 🇯🇵
Japan Organaization of Occupational Health and Safety(JOHAS), Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy